Q1 2023 Non-GAAP Operating Income

Teva Innovative Medicine Pipeline By development stage - as of May 1, 2023 Preclinical Phase 1 Under Regulatory Phase 2 Phase 3 Pre-Submission Review TEV-56278 Oncology TEV-56279 Neuroscience TEV-56288 Neuroscience TEV-48438 Schizophrenia TEV-53408 Gastrointestinal TEV-562861 Multiple System Atrophy TEV-56192 Neuroscience Anti-TL1-A (TEV-48574) Ulcerative Colitis Crohn's Disease Olanzapine LAI Schizophrenia ICS-SABA (TEV-56248) Asthma DigihalerⓇ (beclomethasone dipropionate HFA) (U.S.) Asthma DigihalerⓇ (budesonide and formoterol fumarate dihydrate)² (EU) Asthma & COPD TEV-562871 Parkinson's Disease TEV-46000 Neuroscience | 13 | TECHNOLOGY PLATFORMS Novel Biologic Small Digital Molecule Respiratory Pipeline is current as of May 1, 2023 1) In collaboration with MODAG. 2) Digital component approved in UK by MHRA. Teva innovative medicine pipeline by development stage, excluding country/regional launches of products submitted or under review in new markets. teva

View entire presentation